FactSet Research Likely To Report Higher Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Author: Avi Kapoor | September 16, 2024 10:14am

FactSet Research Systems Inc. (NYSE:FDS) will release earnings results for its fourth quarter, before the opening bell on Thursday, Sept. 19.

Analysts expect the Norwalk, Connecticut-based company to report quarterly earnings at $3.62 per share, down from $2.93 per share in the year-ago period. FactSet Research is projected to post revenue of $546.81 million, compared to $535.8 million a year earlier, according to data from Benzinga Pro.

On Aug. 5, FactSet named Kristina Karnovsky as Head of the Dealmakers and Wealth Group.

FactSet Research shares rose 1.3% to close at $445.36 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• Morgan Stanley analyst Toni Kaplan maintained an Underweight rating and raised the price target from $350 to $355 on June 24. This analyst has an accuracy rate of 74%.
• RBC Capital analyst Ashish Sabadra reiterated a Sector Perform rating with a price target of $464 on June 24. This analyst has an accuracy rate of 70%.
• Wolfe Research analyst Scott Wurtzel initiated coverage on the stock with an Underperform rating and a price target of $430 on April 11. This analyst has an accuracy rate of 69%.
• BMO Capital analyst Jeffrey Silber maintained a Market Perform rating and increased the price target from $447 to $458 on March 25. This analyst has an accuracy rate of 73%.
• Stifel analyst Shlomo Rosenbaum reiterated a Hold rating with a price target of $469 on March 22. This analyst has an accuracy rate of 72%.

Considering buying FDS stock? Here’s what analysts think:

Read This Next:

• Jim Cramer: ‘Hold On’ To Builders FirstSource, ‘Here’s The Problem’ With Viking Therapeutics

Posted In: FDS